Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could curb binge eating episodes

NCT ID NCT05118906

Disease control Sponsor: Bioprojet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a new drug called BP1.4979 in 67 women with moderate to severe binge eating disorder. Participants took either the drug or a placebo for a set period. Researchers measured how many binge eating episodes and days per week occurred, along with quality of life. The goal is to see if the drug can safely reduce binge eating.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BP1.4979 (a drug taken as tablets)
What this could lead to
If successful, this could point toward a new medication to help control binge eating episodes in people with binge eating disorder.
What could go wrong
This is a small, early-phase pilot study with only 67 women, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

67 people

The number who actually took part.

Started

Mar 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to beginning any protocol required procedures. * Female aged between 18 and 65 years, inclusive. * Diagnosis of BED according to DSM-5 criteria * BMI \< 50 kg/m2. Exclusion Criteria: * Current diagnosis of bulimia nervosa or anorexia nervosa. * History of bariatric surgery. * Patient who is pregnant, lactating, or of childbearing potential who is not using adequate contraceptive measures. The following are considered adequate methods of birth control: 1. intrauterine device (IUD); 2. barrier protection; 3. contraceptive implantation system; 4. oral contraceptive pills; 5. surgically sterile patient; and 6. abstinence. All participants should have a negative pregnancy test prior to randomization * Ongoing alcohol or tobacco addiction treatment (except Nicotine Replacement Therapy \[NRT\] with at least one-month stable dose prior to screening visit).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Binge-eating disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

binge eating disorder Binge-Eating Disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Binge-eating disorder

Contacts and locations

Locations

  • Nutrition Department, La Pitié Salpêtrière Hospital

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.